Lysophosphatidic acid receptor 1 antagonist SAR100842 for patients with diffuse cutaneous systemic sclerosis: a double‐blind, randomized, eight‐week placebo …
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-02-20 09:59:12 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
Y Allanore, O Distler, A Jagerschmidt…
Arthritis & …, 2018
Wiley Online Library
Objective Preclinical studies suggest a role for lysophosphatidic acid (LPA) in the pathogenesis of systemic sclerosis (SS c). We undertook this study to assess SAR 100842, a potent selective oral antagonist of the LPA 1 receptor, for safety, biomarkers, and clinical efficacy in patients with diffuse cutaneous SS c (dc SS c). Methods An 8‐week double‐blind, randomized, placebo‐controlled study followed by a 16‐week open‐label extension with SAR 100842 was performed in patients with early dc SS c who had a baseline modified …
